Human Embryonic Stem Cells Market
The market for human embryonic stem cells was estimated at US$ 1,058.9 million in 2021 and is anticipated to grow at a CAGR of 9.2% from 2022 to 2028 to reach US$ 1,955.3 million. Because more attention is being paid to the global development of stem cell therapeutics, the market for human embryonic stem cells is expanding rapidly. Additionally, the prevalence of cardiac and cancerous disorders is likely to rise, and the demand for regenerative therapies is anticipated to expand globally. However, the market for human embryonic stem cells is projected to be hampered by the high cost of the technique, strict regulatory requirements, and ethical concerns.
Click Here for Free Sample Copy (Use corporate email ID Get Higher Priority) @ https://www.coherentmarketinsights.com/insight/request-sample/5275
Market Regional Insights
The global market for human embryonic stem cells is divided into five regions based on geography: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa.
Due to the high incidence of cardiac and cancerous illnesses and the increased attention being paid to the development of cell line-based treatments in this area, particularly in the United States, North America is predicted to obtain the largest market share throughout the projection period. Human embryonic stem cells (hESC), for instance, have a great potential for use in treatment and might eventually become the norm for treating various disorders. One of the top causes of mortality in the US is heart disease. One person passes away every 34 seconds, according to the Centers for Disease Control and Prevention (CDC).
A large portion of the worldwide market for human embryonic stem cells is anticipated to expand in the Asia Pacific area as a result of the region’s growing chronic illness burden and government funding for hESC research. For instance, the Global Institute of Stem Cell Therapy and Research (GIOSTAR) opened a new centre for cancer research and treatment in India in February 2020. This facility is the most recent development in GIOSTAR’s ongoing attempts to expand internationally, which have been active in India, Mexico, the US, and many other nations. It is the most recent of several hospitals being opened around the nation.
Market Drivers
Over the course of the projected period, it is anticipated that the incidence and prevalence of cardiac and cancerous illnesses would rise globally. Human embryonic stem cells (hESC) have a significant therapeutic potential and have the potential to replace current therapies for cardiac/cancerous disorders. The World Health Organization (WHO) reports that heart disorders are one of the main causes of mortality globally, claiming an estimated 17.9 million lives annually and accounting for 32% of all fatalities globally.
Over the course of the projected period, rising regenerative medicine demand is anticipated to fuel market expansion for human embryonic stem cells. For instance, the Government of India assisted in the establishment of cutting-edge stem cell research facilities in 40 renowned health research and educational institutes in February 2022 as part of an effort to boost the country’s research and development (R&D) in regenerative medicine. Additionally, it has invested around Rs. 8.13 billion through the Indian Council of Medical Research (ICMR) in a number of initiatives.
For More Information or Query or Customization before Buying, Visit at – https://www.coherentmarketinsights.com/insight/talk-to-analyst/5275
Market Opportunities
Positive government efforts or an increase in support from governmental or private organisations are anticipated to present companies in the global human embryonic stem cells market with attractive development prospects. For instance, the Murdoch Children’s Research Centre has announced the commencement of a worldwide stem cell research cooperation in June 2022 that aims to create novel therapies for cardiovascular, diabetic, and cancer disorders (MCRI). The Novo Nordisk Foundation provided a record stem cell medicine grant to the institution totaling €300 million over 10 years.
The market for human embryonic stem cells players is anticipated to benefit significantly from the increased attention on the development of stem cell therapeutics. For instance, the future of medicine is in embryonic stem cells. The therapeutic use of these cells is possible. About US$ 80 million was obtained by Cellino Biotech in a Series A investment transaction in January 2022. In order to increase access to stem cell-based medicines, Cellino Biotech intended to construct the first autonomous human cell foundry in 2025.
Market Trends
Different stem cell types are applied in therapeutic settings. Many pharmaceutical and biopharmaceutical firms across the world are actively investigating these cells because to their numerous potential uses at the clinical stage for treating a variety of ailments. Due to the rise in cardiovascular and malignant illnesses such cancer, heart disease, diabetes, and others, as well as the expectation that this trend will continue during the projection period, stem cell biology research will see improved growth.
The success of human embryonic stem cells and technical developments in the stem cell field have led to an increase in the number of clinical studies being conducted worldwide. Predictive models and new/innovative embryonic stem cells can be tested in clinical trials more effectively thanks to artificial intelligence (AI) approaches. AI is being used by researchers all across the world to assess stem cell-based treatments for disorders of the immune system, eyes, and the cardiovascular system.
Market Restraints
The worldwide market for human embryonic stem cells is anticipated to expand slowly due to strict regulatory requirements and ethical concerns. All institutions doing this type of study were asked by the National Academies to form oversight committees to guarantee that the rules will be adhered to. Guidelines are designed to improve the integrity of privately sponsored hESC research by promoting acceptable methods, according to the National Research Council and Institute of Medicine. Any kind of stem cell clinical experiment must wait around a year to receive DCGI (Drugs Control General of India) permission.
The procedure’s high cost is anticipated to impede the market’s expansion for human embryonic stem cells globally. For instance, the price of making and banking stem cells is very high. The price of stem cell treatment might range from US$ 5000 to US$ 50,000. However, the cost of therapy will vary greatly based on a wide range of conditions. Even more expensive than the medium used in the production of human embryonic stem cells. Just 500ml of Thermo Fischer medium cost about INR 32,954. The price of producing hESC serves as a roadblock to the market’s expansion for human embryonic stem cells.
Market Segmentation
The product and geography categories are used to segment the market report on human embryonic stem cells.
The market is divided into Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing based on the kind of product. Due to the increasing need for regenerative medicines throughout the world, the Regenerative Medicine Segment is anticipated to dominate the global market for human embryonic stem cells over the forecast period. hESC has enormous potential for regenerative medicine and may help cure myocardial infarction, diabetes, neurological disorders, stroke, and other well-known human illnesses.
Due to the rise in stem cell biology research, the segment for stem cell biology research is also anticipated to have considerable growth throughout the projection period. Due to the rise in cardiac and cancerous conditions, stem cell biology research will see improved growth.
Key Developments
Thermo Fisher Scientific Inc. and QIAGEN N.V. amended their acquisition agreement in July 2020, and as a result, Thermo Fisher has started a tender offer to buy all of QIAGEN’s ordinary shares.
To provide innovative allogeneic T-cell treatments produced from stem cells to cancer patients, Astellas Pharma Inc. and Adaptimmune Therapeutics Plc. agreed into a co-development and co-commercialization agreement in January 2020.
Key Companies Insights
The market for human embryonic stem cells is quite cutthroat. The market’s participants are concentrating on introducing unique items as a consequence of the rise in the occurrence of cardiac and cancerous disorders.
STEMCELL Technologies Inc., Takara Bio Inc., Lineage Cell Therapeutics Inc., ViaCyte Inc., Thermo Fisher Scientific, PromoCell GmbH, Astellas Pharma Inc., Merck KgaA, and PeproTech Inc. are a few of the major companies in the worldwide market for human embryonic stem cells.
Avail 40% Discount on various license types on Immediate Purchase @ https://www.coherentmarketinsights.com/promo/buynow/5275
Table of Contents:
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product
- Market Snippet, By Geography
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increase in incidence/prevalence of cardiac and malignant diseases
- Stringent regulatory guidelines and ethical issues
- Rise in support from governments or private organisations
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Market Dynamics
- Global Human Embryonic Stem Cells Market – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
- Global Human Embryonic Stem Cells Market, By Product, 2017-2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Regenerative Medicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
- Stem Cell Biology Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
- Tissue Engineering
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
- Toxicology Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/human-embryonic-stem-cells-market-4571
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837